STAT+：自体免疫细胞疗法试验出现两例死亡后，Artiva 正在关停
摘要
Artiva Biotherapeutics 周二表示，在针对自身免疫性疾病的细胞疗法试验中两名患者死亡后，该公司正在逐步关停。这是这一前景广阔的研究领域近期出现的一系列安全事件中的最新一起。这项 2 期研究中的一名参与者在接受治疗后死于神经系统并发症，该疗法为 NK 细胞疗法。Artiva 表示，研究人员确定该死亡很可能与细胞疗法本身无关，而是与细胞疗法之前给予的化疗有关。在输注细胞疗法前给患者进行化疗以降低白细胞计数并为新细胞腾出空间是标准操作。第二名参与者在治疗后约两个月发生猝死。研究人员确定这与治疗无关。
English
Artiva Biotherapeutics said Tuesday that it’s winding down after two patients died in a trial testing its cell therapy for autoimmune diseases, the latest in a series of safety events that have emerged in a promising research field. One participant in the Phase 2 study died from a neurological complication after receiving the treatment, an NK cell therapy. Researchers determined the death was likely not related to the cell therapy itself, but to a chemotherapy that was given before the cell therapy, Artiva said. It’s standard to give patients chemotherapies before infusing cell therapies to lower the patients’ white blood cell count and make room for the new cells. A second participant experienced sudden death about two months after treatment. Researchers determined that this was not relat